539 related articles for article (PubMed ID: 16959959)
1. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
2. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
3. Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.
Mignon L; Wolf WA
Psychopharmacology (Berl); 2002 Aug; 163(1):85-94. PubMed ID: 12185404
[TBL] [Abstract][Full Text] [Related]
4. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Jones CA; Johnston LC; Jackson MJ; Smith LA; van Scharrenburg G; Rose S; Jenner PG; McCreary AC
Eur Neuropsychopharmacol; 2010 Aug; 20(8):582-93. PubMed ID: 20434890
[TBL] [Abstract][Full Text] [Related]
5. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
Jackson MJ; Al-Barghouthy G; Pearce RK; Smith L; Hagan JJ; Jenner P
Pharmacol Biochem Behav; 2004 Nov; 79(3):391-400. PubMed ID: 15582011
[TBL] [Abstract][Full Text] [Related]
6. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
7. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
Iravani MM; Costa S; Al-Bargouthy G; Jackson MJ; Zeng BY; Kuoppamäki M; Obeso JA; Jenner P
Eur J Neurosci; 2005 Sep; 22(6):1305-18. PubMed ID: 16190886
[TBL] [Abstract][Full Text] [Related]
8. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
9. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
10. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Tayarani-Binazir K; Jackson MJ; Rose S; McCreary AC; Jenner P
Exp Neurol; 2010 Dec; 226(2):320-7. PubMed ID: 20843474
[TBL] [Abstract][Full Text] [Related]
11. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
Eskow KL; Gupta V; Alam S; Park JY; Bishop C
Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
[TBL] [Abstract][Full Text] [Related]
12. Involvement of 5-hydroxytryptamine1A receptors in Delta9-tetrahydrocannabinol-induced catalepsy-like immobilization in mice.
Egashira N; Matsuda T; Koushi E; Mishima K; Iwasaki K; Shoyama Y; Fujiwara M
Eur J Pharmacol; 2006 Nov; 550(1-3):117-22. PubMed ID: 17022969
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets.
Jackson MJ; Smith LA; Al-Barghouthy G; Rose S; Jenner P
Exp Neurol; 2007 Mar; 204(1):162-70. PubMed ID: 17113078
[TBL] [Abstract][Full Text] [Related]
14. Evidence that the 5-HT1A autoreceptor is an important pharmacological target for the modulation of cocaine behavioral stimulant effects.
Carey RJ; DePalma G; Damianopoulos E; Shanahan A; Müller CP; Huston JP
Brain Res; 2005 Feb; 1034(1-2):162-71. PubMed ID: 15713268
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
Tayarani-Binazir KA; Jackson MJ; Rose S; Olanow CW; Jenner P
Mov Disord; 2010 Feb; 25(3):377-84. PubMed ID: 20108359
[TBL] [Abstract][Full Text] [Related]
16. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
[TBL] [Abstract][Full Text] [Related]
17. Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications.
Ba M; Kong M; Ma G; Yang H; Lu G; Chen S; Liu Z
Brain Res; 2007 Jan; 1127(1):177-84. PubMed ID: 17113046
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
Blanchet P; Bédard PJ; Britton DR; Kebabian JW
J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
[TBL] [Abstract][Full Text] [Related]
19. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
20. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
